<p>/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT)，一家全球领先的商业阶段抗体药物偶联物（ADCs）领域的先锋，今天宣布公司已于 2025 年 4 月 1 日向两名新员工授予了总计 128,600 股公司普通股的购买期权（每项称为 “授予”）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2543351/ADC_Therapeutics_SA__logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2543351/ADC_Therapeutics_SA__logo.jpg"/></p>
<p>这些授予是作为对员工就业的实质性诱因。授予经过公司董事会薪酬委员会的批准，依据公司的诱因计划，以激励和奖励受赠人以最高水平表现并为公司的成功做出重大贡献。这些授予是基于纽约证券交易所上市公司手册第 303A.08 条款下的就业诱因豁免而作出的。</p>
<p>公司根据第 303A.08 条款发布本新闻稿。这些授予将在授予日期的第一周年时生效并可行使 25%，之后在每个月的周年日生效并可行使授予总数的 1/48，直到授予日期的第四周年时，整个奖励将完全生效，前提是继续在公司工作。</p>
<p><strong>关于 ADC Therapeutics</strong></p>
<p>ADC Therapeutics（NYSE: ADCT）是一家全球领先的商业阶段抗体药物偶联物（ADCs）领域的先锋。公司正在推进其专有的 ADC 技术，以改变血液恶性肿瘤和实体肿瘤患者的治疗模式。</p>
<p>ADC Therapeutics 的 CD19 靶向 ADC ZYNLONTA（loncastuximab tesirine-lpyl）已获得 FDA 的加速批准和欧洲委员会的有条件批准，用于治疗经过两条或更多系统治疗后复发或难治性弥漫大 B 细胞淋巴瘤。ZYNLONTA 还在与其他药物联合开发以及早期治疗中进行研究。除了 ZYNLONTA，ADC Therapeutics 还有多个 ADC 正在进行临床和临床前开发。</p>
<p>ADC Therapeutics 总部位于瑞士洛桑（Biopôle），并在伦敦和新泽西州开展业务。欲了解更多信息，请访问 https://adctherapeutics.com/ 并在 LinkedIn 上关注公司。</p>
<p>ZYNLONTA®是 ADC Therapeutics SA 的注册商标。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1995 年私人证券诉讼改革法案的安全港条款的前瞻性声明。在某些情况下，您可以通过术语如 “可能”、“将”、“应该”、“会”、“期望”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“潜在”、“似乎”、“寻求”、“未来”、“继续” 或 “出现” 或这些术语的否定形式或类似表达来识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。前瞻性声明受到某些风险和不确定性的影响，这可能导致实际结果与所描述的结果有重大差异。可能导致此类差异的因素包括但不限于：预计的现金流持续到 2026 年中期，公司在美国增长 ZYNLONTA®收入的能力；我们合作伙伴在国外市场商业化 ZYNLONTA®的能力，未来收入和付款的时间和金额，以及他们在外国司法管辖区获得 ZYNLONTA®监管批准的能力；公司或其合作伙伴的研究和开发项目或临床试验的时间和结果，包括 LOTIS 5 和 7、ADCT 602，以及在某些实体肿瘤中针对不同靶点、连接子和药物载体的早期研究；研究者发起的试验的时间和结果，包括研究 FL 和 MZL 的试验，以及潜在的监管和/或汇编策略及未来机会；公司产品或产品候选人的监管提交的时间和结果；FDA 或外国监管机构的行动；预计的收入和支出；公司的债务，包括医疗特许权管理和 Blue Owl 及 Oaktree 设施，以及这些债务对公司活动施加的限制，遵守各种协议条款和偿还这些债务的能力，以及服务这些债务所需的巨额现金；以及公司获得其研究、开发、临床和商业活动的财务和其他资源的能力。有关这些和其他可能导致实际结果与前瞻性声明中预期结果有重大差异的因素的更多信息，请参阅公司在 10-K 表格中的 “风险因素” 部分以及公司向美国证券交易委员会提交的其他定期和当前报告及文件。这些声明涉及已知和未知的风险、不确定性和其他因素，可能导致实际结果、表现、成就或前景与前瞻性声明中表达或暗示的任何未来结果、表现、成就或前景有重大不同。公司提醒投资者不要对本文件中包含的前瞻性声明过度依赖。</p>
<p><strong>联系方式：</strong></p>
<p><strong>投资者</strong> Marcy Graham</p>
<p>ADC Therapeutics</p>
<p>Marcy.Graham@adctherapeutics.com</p>
<p>+1 650-667-6450</p>
<p><strong>媒体</strong> Nicole Riley</p>
<p>ADC Therapeutics</p>
<p>Nicole.Riley@adctherapeutics.com</p>
<p>+1 862-926-9040</p>
<p>来源：ADC Therapeutics SA</p>

ADCT

<p>ADC Therapeutics SA（纽约证券交易所代码：ADCT）宣布向两名新员工授予购买 128,600 股普通股的期权，以作为其入职的诱因。该授予经过薪酬委员会批准，旨在激励和奖励受赠者。这些期权将在第一周年时归属 25%，随后每月归属，至第四周年时完全归属，前提是员工继续在职。ADC Therapeutics 是抗体药物偶联物领域的领导者，其产品 ZYNLONTA 已获得 FDA 加速批准，用于治疗某些淋巴瘤</p>

<p>, /PRNewswire/ --ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 128,600 of the Company's common shares to two new employees on April 1, 2025 (each, a &#34;Grant&#34;).</p>
<div class="lb-trans"><p>/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT)，一家全球领先的商业阶段抗体药物偶联物（ADCs）领域的先锋，今天宣布公司已于 2025 年 4 月 1 日向两名新员工授予了总计 128,600 股公司普通股的购买期权（每项称为 “授予”）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2543351/ADC_Therapeutics_SA__logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2543351/ADC_Therapeutics_SA__logo.jpg"/></p>
<p>The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08.</p>
<div class="lb-trans"><p>这些授予是作为对员工就业的实质性诱因。授予经过公司董事会薪酬委员会的批准，依据公司的诱因计划，以激励和奖励受赠人以最高水平表现并为公司的成功做出重大贡献。这些授予是基于纽约证券交易所上市公司手册第 303A.08 条款下的就业诱因豁免而作出的。</p>
</div><p>The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.</p>
<div class="lb-trans"><p>公司根据第 303A.08 条款发布本新闻稿。这些授予将在授予日期的第一周年时生效并可行使 25%，之后在每个月的周年日生效并可行使授予总数的 1/48，直到授予日期的第四周年时，整个奖励将完全生效，前提是继续在公司工作。</p>
</div><p><strong>About ADC Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 ADC Therapeutics</strong></p>
</div><p>ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.</p>
<div class="lb-trans"><p>ADC Therapeutics（NYSE: ADCT）是一家全球领先的商业阶段抗体药物偶联物（ADCs）领域的先锋。公司正在推进其专有的 ADC 技术，以改变血液恶性肿瘤和实体肿瘤患者的治疗模式。</p>
</div><p>ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.</p>
<div class="lb-trans"><p>ADC Therapeutics 的 CD19 靶向 ADC ZYNLONTA（loncastuximab tesirine-lpyl）已获得 FDA 的加速批准和欧洲委员会的有条件批准，用于治疗经过两条或更多系统治疗后复发或难治性弥漫大 B 细胞淋巴瘤。ZYNLONTA 还在与其他药物联合开发以及早期治疗中进行研究。除了 ZYNLONTA，ADC Therapeutics 还有多个 ADC 正在进行临床和临床前开发。</p>
</div><p>ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.</p>
<div class="lb-trans"><p>ADC Therapeutics 总部位于瑞士洛桑（Biopôle），并在伦敦和新泽西州开展业务。欲了解更多信息，请访问 https://adctherapeutics.com/ 并在 LinkedIn 上关注公司。</p>
</div><p>ZYNLONTA® is a registered trademark of ADC Therapeutics SA.</p>
<div class="lb-trans"><p>ZYNLONTA®是 ADC Therapeutics SA 的注册商标。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as &#34;may&#34;, &#34;will&#34;, &#34;should&#34;, &#34;would&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;plan&#34;, &#34;anticipate&#34;, &#34;believe&#34;, &#34;estimate&#34;, &#34;predict&#34;, &#34;potential&#34;, &#34;seem&#34;, &#34;seek&#34;, &#34;future&#34;, &#34;continue&#34;, or &#34;appear&#34; or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, ADCT 602 as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the &#34;Risk Factors&#34; section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年私人证券诉讼改革法案的安全港条款的前瞻性声明。在某些情况下，您可以通过术语如 “可能”、“将”、“应该”、“会”、“期望”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“潜在”、“似乎”、“寻求”、“未来”、“继续” 或 “出现” 或这些术语的否定形式或类似表达来识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。前瞻性声明受到某些风险和不确定性的影响，这可能导致实际结果与所描述的结果有重大差异。可能导致此类差异的因素包括但不限于：预计的现金流持续到 2026 年中期，公司在美国增长 ZYNLONTA®收入的能力；我们合作伙伴在国外市场商业化 ZYNLONTA®的能力，未来收入和付款的时间和金额，以及他们在外国司法管辖区获得 ZYNLONTA®监管批准的能力；公司或其合作伙伴的研究和开发项目或临床试验的时间和结果，包括 LOTIS 5 和 7、ADCT 602，以及在某些实体肿瘤中针对不同靶点、连接子和药物载体的早期研究；研究者发起的试验的时间和结果，包括研究 FL 和 MZL 的试验，以及潜在的监管和/或汇编策略及未来机会；公司产品或产品候选人的监管提交的时间和结果；FDA 或外国监管机构的行动；预计的收入和支出；公司的债务，包括医疗特许权管理和 Blue Owl 及 Oaktree 设施，以及这些债务对公司活动施加的限制，遵守各种协议条款和偿还这些债务的能力，以及服务这些债务所需的巨额现金；以及公司获得其研究、开发、临床和商业活动的财务和其他资源的能力。有关这些和其他可能导致实际结果与前瞻性声明中预期结果有重大差异的因素的更多信息，请参阅公司在 10-K 表格中的 “风险因素” 部分以及公司向美国证券交易委员会提交的其他定期和当前报告及文件。这些声明涉及已知和未知的风险、不确定性和其他因素，可能导致实际结果、表现、成就或前景与前瞻性声明中表达或暗示的任何未来结果、表现、成就或前景有重大不同。公司提醒投资者不要对本文件中包含的前瞻性声明过度依赖。</p>
</div><p><strong>CONTACTS:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p><strong>Investors</strong> Marcy Graham</p>
<div class="lb-trans"><p><strong>投资者</strong> Marcy Graham</p>
</div><p>ADC Therapeutics</p>
<div class="lb-trans"><p>ADC Therapeutics</p>
</div><p>Marcy.Graham@adctherapeutics.com</p>
<div class="lb-trans"><p>Marcy.Graham@adctherapeutics.com</p>
</div><p>+1 650-667-6450</p>
<div class="lb-trans"><p>+1 650-667-6450</p>
</div><p><strong>Media</strong> Nicole Riley</p>
<div class="lb-trans"><p><strong>媒体</strong> Nicole Riley</p>
</div><p>ADC Therapeutics</p>
<div class="lb-trans"><p>ADC Therapeutics</p>
</div><p>Nicole.Riley@adctherapeutics.com</p>
<div class="lb-trans"><p>Nicole.Riley@adctherapeutics.com</p>
</div><p>+1 862-926-9040</p>
<div class="lb-trans"><p>+1 862-926-9040</p>
</div><p>SOURCE ADC Therapeutics SA</p>
<div class="lb-trans"><p>来源：ADC Therapeutics SA</p>
</div>

ADC Therapeutics 根据诱导计划向新员工授予补助 | ADCT 股票新闻